Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pirfenidone in the Treatment of Hermansky Pudlak Syndrome (HPS) - Related Interstitial Lung Disease (ILD)

NCT04193592 is registered in ClinicalTrials.gov with Jesse Roman as lead sponsor.

NCT NCT04193592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04193592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pirfenidone in the Treatment of Hermansky Pudlak Syndrome (HPS) - Related Interstitial Lung Disease (ILD)
Lead sponsor
Jesse Roman
Phase
Phase 2
Overall status
Unknown status
Start date
December 1, 2019
Completion date
December 31, 2022
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hermansky pudlak syndrome, interstitial lung disease